Replimune Announces Sander Slootweg will Depart from its Board of Directors
20. Juli 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
06. Juni 2023 10:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
05. Juni 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
03. Juni 2023 14:15 ET
|
Replimune Group Inc
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no...
Replimune to Present at the Jefferies Global Healthcare Conference
01. Juni 2023 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
25. Mai 2023 17:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
18. Mai 2023 08:00 ET
|
Replimune Group Inc
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
09. Mai 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at Two Upcoming Investor Conferences
08. März 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
09. Februar 2023 08:00 ET
|
Replimune Group Inc
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline...